Phesi, a global provider of patient-centric data analytics, has uncovered the urgent need for the clinical trials industry to address the issue of single-patient enrolment
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh